预防性抗乙肝病毒治疗与接受经动脉化疗的肝细胞癌患者长期生存改善相关
本研究基于2002至2016年2860例新诊断HBV相关肝细胞癌并接受经动脉化疗的患者,按是否预防性使用抗病毒药物分组,经倾向评分匹配(1:1)分析。结果显示预防性抗病毒治疗组总生存显著更长,且高 potency 抗病毒药物优于低 potency 药物,该关联在匹配队列及亚组中持续存在。
要点
- 预防性抗病毒治疗与接受经动脉化疗的HBV相关肝细胞癌患者长期生存显著改善相关。
- 高 potency 抗病毒药物较低 potency 药物带来显著更长的生存。
- 无论基线病毒血症状态或肿瘤分期,预防性抗病毒治疗的生存获益均存在。
核心结论
- 预防性抗病毒治疗与接受经动脉化疗的HBV相关肝细胞癌患者长期生存显著改善相关。
- 高 potency 抗病毒药物被推荐用于该预防策略。
研究设计与样本
- 2002至2016年筛查2860例新诊断HBV相关肝细胞癌并接受经动脉化疗的患者,1547例符合纳入标准。
- 按是否预防性使用抗病毒药物分组,并对整个队列及各亚组分别进行倾向评分匹配(1:1),最终1084例匹配。
- 中位随访时间16.55个月,主要终点为总生存。
主要发现
- 在未匹配全队列中,接受预防性抗病毒治疗的患者生存显著长于未接受者。
- 在未接受抗病毒治疗的患者中,基线高病毒血症和治疗期间HBV再激活与更短生存显著相关。
- 高 potency 抗病毒药物组生存较低 potency 药物组显著更长,且生存随抗病毒应答不同而异。
- 在倾向评分匹配队列中,无论病毒状态或肿瘤分期,预防性抗病毒治疗组生存均显著更长,且为生存的独立因素。
- 调整基线危险因素后,预防性抗病毒治疗与死亡风险降低的关联在各亚组中持续存在,敏感性分析证实了估计的治疗效应。
临床怎么用
- 对接受经动脉化疗的HBV相关肝细胞癌患者,应考虑预防性使用高 potency 抗病毒药物以改善长期生存。
- 基线高病毒血症及治疗期间HBV再激活与更短生存相关,应重视病毒监测与预防性治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The effect of prophylactic antiviral therapy (AVT) on survival of patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) remains unknown. This study aimed to determine whether prophylactic AVT could improve long-term survival in patients undergoing transarterial chemotherapy (TAC). METHODS: Between 2002 and 2016, 2860 newly diagnosed HBV-related patients with HCC treated with TAC were screened to analyze 2 groups based on prophylactic use of antivirals. Treatment effects were analyzed using propensity score (PS) matching (1:1) separately for the entire cohort and each subgroup. The primary endpoint was overall survival. RESULTS: A total of 1547 patients met the inclusion criteria and 1084 were PS matched for the 2 groups. Median follow-up duration was 16.55 months. In the entire unmatched cohort, patients receiving prophylactic AVT survived significantly longer than those who did not. Among AVT-untreated patients, baseline high viremia and HBV reactivation during treatment were significantly associated with shorter survival. Regarding types of antivirals, survival was significantly longer for patients receiving high-potency antivirals than those receiving low-potency antivirals. Survival differed with antiviral response. In the PS-matched cohort, the prophylactic AVT group survived significantly longer than the nonprophylactic group, irrespective of viral status or tumor stage. Prophylactic AVT remained an independent factor for survival. The association of prophylactic AVT with decreased risk of mortality persisted in patient subgroups after adjusting for baseline risk factors. Sensitivity analyses also confirmed estimated treatment effects. CONCLUSIONS: Prophylactic AVT is associated with significantly improved long-term survival among patients undergoing TAC. High-potency antivirals are indicated for this approach.Hepatitis B virus-associated morbidity is a well-known complication during transarterial chemotherapy (TAC). Our large-scale study demonstrated that prophylactic therapy with high-potency antivirals provides a significantly better survival in TAC-treated patients, irrespective of baseline viremia status or tumor stage.
引用
- Jang JW, Yoo SH, Nam HC, et al. Association of Prophylactic Anti-Hepatitis B Virus Therapy With Improved Long-term Survival in Patients With Hepatocellular Carcinoma Undergoing Transarterial Therapy. Clin Infect Dis. 2020. PMID: 31504352. doi:10.1093/cid/ciz860
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。